Last reviewed · How we verify

BuCy — Competitive Intelligence Brief

BuCy (BuCy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent combination (chemotherapy conditioning regimen). Area: Oncology.

phase 3 Alkylating agent combination (chemotherapy conditioning regimen) Oncology Biologic Live · refreshed every 30 min

Target snapshot

BuCy (BuCy) — The First Affiliated Hospital of Soochow University. BuCy is a chemotherapy conditioning regimen combining busulfan and cyclophosphamide used to prepare patients for hematopoietic stem cell transplantation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BuCy TARGET BuCy The First Affiliated Hospital of Soochow University phase 3 Alkylating agent combination (chemotherapy conditioning regimen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent combination (chemotherapy conditioning regimen) class)

  1. The First Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BuCy — Competitive Intelligence Brief. https://druglandscape.com/ci/bucy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: